Primary cutaneous acral CD8 positive T cell lymphoproliferative disorder

Last updated
Primary cutaneous acral CD8 positive T cell lymphoproliferative disorder
Other namesPrimary cutaneous acral CD8 positive T cell lymphoma, Indolent CD8+ lymphoid proliferation of the ear
Specialty Dermatology, Oncology
Symptoms Cutaneous nodule or plaque
Usual onsetAdults usually 29 years of age or older
TreatmentSurgery and/or radiotherapy or just observation
Prognosis Good to excellent
FrequencyRare

Primary cutaneous acral CD8 positive T cell lymphoproliferative disorder (CD8+ TLPD) is one type of the lymphoproliferative disorders, subclass cutaneous T-cell lymphoma, in which a slow-growing nodule or papule develops on the ear or, less commonly, other acral sites. CD8 positive T-cells (i.e., CD8+ T-cells) are a subtype of the lymphocytes and acral sites are peripheral parts of the body, i.e., the hands, arms, feet, legs, ears, nose, fingernails, and toenails. [1] In 2007, Petrella et al.,7 [2] reported four patients with tumors composed of CD8+ T-cells and termed the disorder indolent CD8+ lymphoid proliferation of the ear. In 2018, the World Health Organization and European Organisation for Research and Treatment of Cancer provisionally classified this disorder as a lymphoma and termed it primary cutaneous acral CD8 positive T cell lymphoma. [3] (The "primary" used to designate cutaneous lymphomas indicates that the lymphoma was first diagnosed as limited to the skin and there was no evidence of spread to extracutaneous tissues for 6 months after the diagnosis was first made. [4] ) In 2022, however, the International Consensus Classification (ICC) group of experts in various medical fields maintained that this disorder was not malignant and therefore termed it primary cutaneous acral CD8 positive T cell lymphoproliferative disorder. [1] [5] In 2024, the World Health Organization (WHO) agreed with this classification and designation. [6] However, histiocyte and CD8 T-cell-rich lymphoproliferations of the skin in individuals with primary immunodeficiency (i.e., individuals born with an immunodeficiency due to genetic causes), which had been regarded as a form of CD8+ TLPD, was reclassified as one of the inborn error of immunity-associated lymphoproliferative disorders by the WHO (2022) classification of hematolymphoid tumors. [6] [7] That is, it is now designated as a histiocyte and CD8 T-cell rich lymphoproliferative disorder in patients due to their having an inborn error of immunity. [8] Here, these ICC and WHO classifications are followed, i.e., primary cutaneous acral CD8 positive T cell lymphoma is termed primary cutaneous acral CD8 positive T cell lymphoproliferative disorder and histiocyte and CD8-rich and T-cell-rich lymphoproliferations in associated with a congenital immunodeficiency are not considered to be a form of CD8+ TLPD.

Contents

The correct diagnosis of CD8+ TLPD is crucial because of its far more benign clinical behavior than many other types of similarly appearing CD8+ T-cell lymphomas. [9] [10] [11] [12] [13]

Presentation

At presentation, 31 patients with CD8+ TLPD were 29–89 years old (average 52.1 years); 23 were male, 8 were female; 26 had nodules, 5 had plaques; 28 had a single lesion, 2 had bilateral lesions, and 1 had multiple lesions; 18 had a single lesion on the ear, 3 had a single lesion on the nose, 1 had a single lesion on the leg, 4 had a single lesion on the foot, 2 had a single lesion on the arm, 1 had a single lesion on the hand, 1 had a single lesion on a non-acral site behind the ear, and 1 had disseminated lesions at non-acral sites on the head and neck. Among the 26 patients for which this data was available, their lesions had begun and slowly increased in size for 3 to 420 months (median duration 12 months) prior to their being diagnosed. [14] Rarely, patients have also presented with CD8+ TLPD lesions on two other non-acral sites, the thigh or eyelid. [15] TCD8+ TLPD lesions have presented as reddish/purple nodules or plaques measuring up to several centimeters in maximal dimension. [1] These lesions are not ulcerated, i.e., do not have ulcers. [9] Various analyses to define the patients stage, (i.e., extent of disease) at presentation using computed tomography scans and/or bone marrow examinations almost uniformly found that at presentation or thereafter the lesions had not spread to non-cutaneous sites. [14] [16] [17] [18] About 20% of patients that had their CD8+ TLPD lesions disappear in response to treatment will have purely cutaneous recurrences of their lesions. [14] As of 2022, [5] only one patient, after a long history of being repeatedly treated for cutaneous recurrences of CD8+ TLPD, developed a subcutaneous spread of a CD8+ TLPD nasal lesion into the nearby nasal bone and cartilage. [5] [19]

Histopathology and immunochemistry

The microscopic histopathology (i.e., examination) of CD8+ TLPD lesions commonly shows a dense infiltration of similarly appearing, medium-sized (or in uncommon cases large or small [14] ) CD+ T-cells. [18] [2] [5] [13] In some cases, these T-cells have a monocyte-like appearance and nuclei that are eccentrically located and kidney-shaped. [15] The lesions may also show small collections of B lymphocytes [18] but have few plasma cells or eosinophils. [15] The lesions show no evidence that their cells have invaded blood vessels. [1] In three reported cases, there was an extension of the infiltrate into the nearby subcutaneous fat tissue. The growth rate of these T-cells, as measured by their tissues' proliferation index (a histopathological measurement of how many cells in the lesions are dividing into two daughter cell) or Ki-67 (a measure of the proliferation rate of the lesions individual cells) is usually low. [14] [18] The lesions do not have areas of necrosis, i.e., clumps of dead cells. [9] Analyses of the lesions using immunochemistry methods indicate that their cells do not express cytosol protein perforin nor, in most cases, the granule-bound protein granzyme B. [2] [7] [20] The T-cells in these lesions do express T-cell receptor proteins, CD8 (a transmembrane glycoprotein that is a co-receptor for the T-cell receptor), TIA-1 (i.e., a granule-bound mRNA-binding protein), and in almost all cases (e.g., 26 of 28 cases in one study), the CD68 glycoprotein which is distributed in an unusual and distinctive dot-like pattern around the cell's nucleus. [1] [14] [15] [19] [20] [21]

Diagnosis

The diagnosis of CD8+ TLPD is strongly dependent on finding that: a) it presents as a very slowly growing and usually single nodule or plaque that consists of CD8+ T cells in the cutaneous tissues primarily but not exclusively of acral sites, particularly the ear, in adults; [14] b) the cells in these lesions are predominantly CD8+ T-cells that typically have a low growth rate but otherwise have some features that resemble those found in malignant lymphomas; [9] c) the lesions' T-cells cells express CD3, CD8, and TIA-1 but not perforin nor in most cases, granzyme B; [15] d) most cases of CD8+ TLPD express CD68 in a characteristic perinuclear dot-like pattern which is rarely found in other cutaneous T cell lymphomas and therefore a good indicator of CD8+ TLPD; [1] [20] and e) its T cells usually express CD3, often do not express one or more of the CD2, CD5 and CD7 proteins, and do not express CD30, CD56, B3GAT1 (i.e., CD57), or terminal deoxynucleotidyl transferase (i.e., TdT). [1] [18] These features of CD8+ TLPD typically distinguish it from similarly appearing but aggressive CD8 T cell lymphomas [9] such as primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, [10] the peripheral T-cell lymphoma not otherwise specified in the subtype of this lymphoma that consists of CD8+ T-cells, [11] [9] [12] [13] the CD8-expressing variants of mycosis fungoides which in about 4% of cases progress to more extensive disorders that are treated aggressively, [12] subcutaneous panniculitis-like T-cell lymphoma, the subcutaneous form of anaplastic large cell lymphomas, [9] and primary cutaneous small/medium-sized pleomorphic cutaneous T-cell lymphoma. [9] [22]

Treatment and prognosis

Patients with CD8+ TLPD have been treated with surgical excision, radiation therapy, photodynamic therapy, PUVA ultraviolet light therapy, topical steroids, and anti-cancer drugs (e.g., bexarotene, pralatrexate, methotrexate, chlormethine, doxorubicin, gemcitabine, oxaliplatin, and the CHOP chemotherapy regimen). [13] [19] [23] However, CD8+ TLPD is almost always a benign disorder that may relapse after treatment but rarely if ever disseminates to extracutaneous tissues. [1] Indeed, CD8+ TLPD lesions have slowly disappeared after being biopsied but not further treated in about 10% of cases [7] and in one study 71% of patients with CD8+ TLPD had complete disease remissions following their treatment. [14] Because of its very indolent course, the use of aggressive therapies (e.g., anti-cancer drugs) to treat CD8+ TLPD is not recommended. [15] Rather, studies have concluded that CD8+ TLPD lesions should be treated with local therapies (i.e., surgical removal and/or localized radiation) [3] [20] or even long-term observations without treatment. [5] [9] It has also been recommended that clinical staging (i.e., examinations to determine the extent of disease) is unnecessary in cases presenting with the typical clinical presentation and histology of CD8+ TLPD. [3] [14]

Related Research Articles

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Tumors that affect the blood, bone marrow, lymph, and lymphatic system

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Mycosis fungoides</span> Most common form of cutaneous T-cell lymphoma

Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell lymphoma. It generally affects the skin, but may progress internally over time. Symptoms include rash, tumors, skin lesions, and itchy skin.

<span class="mw-page-title-main">Cutaneous T-cell lymphoma</span> Type of immune system cancer

Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin lymphomas, CTCL is caused by a mutation of T cells. The cancerous T cells in the body initially migrate to the skin, causing various lesions to appear. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash which can be very itchy and eventually forming plaques and tumors before spreading to other parts of the body.

Lymphoproliferative disorders (LPDs) refer to a specific class of diagnoses, comprising a group of several conditions, in which lymphocytes are produced in excessive quantities. These disorders primarily present in patients who have a compromised immune system. Due to this factor, there are instances of these conditions being equated with "immunoproliferative disorders"; although, in terms of nomenclature, lymphoproliferative disorders are a subclass of immunoproliferative disorders—along with hypergammaglobulinemia and paraproteinemias.

<span class="mw-page-title-main">Sézary disease</span> Medical condition

Sézary disease, or Sézary syndrome, is a type of cutaneous T-cell lymphoma that was first described by Albert Sézary. The affected T cells, known as Sézary's cells or Lutzner cells, have pathological quantities of mucopolysaccharides. Sézary disease is sometimes considered a late stage of mycosis fungoides with lymphadenopathy.

<span class="mw-page-title-main">Intravascular lymphomas</span> Medical condition

Intravascular lymphomas (IVL) are rare cancers in which malignant lymphocytes proliferate and accumulate within blood vessels. Almost all other types of lymphoma involve the proliferation and accumulation of malignant lymphocytes in lymph nodes, other parts of the lymphatic system, and various non-lymphatic organs but not in blood vessels.

<span class="mw-page-title-main">Marginal zone lymphoma</span> Group of lymphomas

Marginal zone lymphomas, also known as marginal zone B-cell lymphomas (MZLs), are a heterogeneous group of lymphomas that derive from the malignant transformation of marginal zone B-cells. Marginal zone B cells are innate lymphoid cells that normally function by rapidly mounting IgM antibody immune responses to antigens such as those presented by infectious agents and damaged tissues. They are lymphocytes of the B-cell line that originate and mature in secondary lymphoid follicles and then move to the marginal zones of mucosa-associated lymphoid tissue (MALT), the spleen, or lymph nodes. Mucosa-associated lymphoid tissue is a diffuse system of small concentrations of lymphoid tissue found in various submucosal membrane sites of the body such as the gastrointestinal tract, mouth, nasal cavity, pharynx, thyroid gland, breast, lung, salivary glands, eye, skin and the human spleen.

<span class="mw-page-title-main">Pagetoid reticulosis</span> Medical condition

Pagetoid reticulosis is a cutaneous condition, an uncommon lymphoproliferative disorder, sometimes considered a form of mycosis fungoides.

Primary cutaneous anaplastic large cell lymphoma belongs to the group of cutaneous processes that are CD30+ lymphoproliferative and are characterized by autoregressive, recurrent, single or multifocal ulcerating nodules. Single or localized nodules, papules, or plaques are present in the majority of patients. However, a patient may have more than one lesion in up to 20% of cases.

<span class="mw-page-title-main">Extranodal NK/T-cell lymphoma, nasal type</span> Medical condition

Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is a rare type of lymphoma that commonly involves midline areas of the nasal cavity, oral cavity, and/or pharynx At these sites, the disease often takes the form of massive, necrotic, and extremely disfiguring lesions. However, ENKTCL-NT can also involve the eye, larynx, lung, gastrointestinal tract, skin, and various other tissues. ENKTCL-NT mainly affects adults; it is relatively common in Asia and to lesser extents Mexico, Central America, and South America but is rare in Europe and North America. In Korea, ENKTCL-NT often involves the skin and is reported to be the most common form of cutaneous lymphoma after mycosis fungoides.

<span class="mw-page-title-main">Cutaneous B-cell lymphoma</span> Medical condition

Cutaneous B-cell lymphomas (CBCL), more recently termed Primary cutaneous B-cell lymphomas and lymphoproliferative disorders (PCBCLPD), are a group of disorders that typically present as skin lesions consisting of proliferating B-cells. B-cells are a type of lymphocyte involved in regulating immune responses. Since its original definition in 1997, CBCL has been considered to have a varying number of subtypes by the European Organisation for Research and Treatment of Cancer, i.e., EORTC, and World Health Organization, i.e., WHO. The latest revised classification of CBCL, which was published by EORTC in 2022, lists the following three main subtypes of CBCL :

Primary cutaneous immunocytoma was initially regarded as a distinct type of the cutaneous lymphomas of the skin. A 1997 review characterized 16 cases of primary cutaneious immunocytomo as skin lesions located on the arms and legs that in 15 of 16 cases had an excellent responses to, and prognoses after, purely local treatments. On microscopic histological examination, these lesions consisted of B cells and nodular or diffuse infiltrates of lymphoplasmacytoid-like plasma cells located at the periphery of these infiltrates. In 2004, however, the World Health Organization and European Organisation for Research and Treatment of Cancer classified primary cutaneous immunocytoma as one form of the primary cutaneous marginal zone lymphomas or, as they are now termed, primary cutaneous marginal zone lymphoproliferative disorders.

Primary cutaneous marginal zone lymphomas represent a heterogeneous group of diseases characterized by solitary or multiple dermal or subcutaneous nodules. Lymphomas included in this group are:

Epstein–Barr virus–associated lymphoproliferative diseases are a group of disorders in which one or more types of lymphoid cells, i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the Epstein–Barr virus (EBV). This causes the infected cells to divide excessively, and is associated with the development of various non-cancerous, pre-cancerous, and cancerous lymphoproliferative disorders (LPDs). These LPDs include the well-known disorder occurring during the initial infection with the EBV, infectious mononucleosis, and the large number of subsequent disorders that may occur thereafter. The virus is usually involved in the development and/or progression of these LPDs although in some cases it may be an "innocent" bystander, i.e. present in, but not contributing to, the disease.

<span class="mw-page-title-main">Mosquito bite allergy</span> Excessive reactions to mosquito bites

Mosquito bite allergies, also termed hypersensitivity to mosquito bites, are excessive reactions of varying severity to mosquito bites. They are allergic hypersensitivity reactions caused by the non-toxic allergenic proteins contained in the saliva injected by a female mosquito at the time it takes its blood meal, and are not caused by any toxin or pathogen. By general agreement, mosquito bite allergies do not include the ordinary wheal and flare responses to these bites although these reactions are also allergic in nature. Ordinary mosquito bite allergies are nonetheless detailed here because they are the best understood reactions to mosquito bites and provide a basis for describing what is understood about them.

Natural killer cell enteropathy, also termed NK cell enteropathy (NKCE), and a closely related disorder, lymphomatoid gastropathy (LG), are non-malignant diseases in which one type of lymphocyte, the natural killer cell, proliferates excessively in the gastrointestinal tract. This proliferation causes red, sore-like spots, raised lesions, erosions, and ulcers in the mucosal layer surrounding the GI tract lumen. Both disorders cause either no or only vague symptoms of GI tract disturbances such as nausea, vomiting, and bleeding.

Indolent T cell lymphoproliferative disorder of the gastrointestinal tract or Indolent T cell lymphoproliferative disorder of the GI tract (ITCLD-GT) is a rare and recently recognized disorder in which mature T cell lymphocytes accumulation abnormally in the gastrointestinal tract. This accumulation causes various lesions in the mucosal layer lining the GI tract. Individuals with ITCLD-GT commonly complain of chronic GI tract symptoms such as nausea, vomiting, diarrhea, abdominal pain, and rectal bleeding.

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a cutaneous lymphoma skin disease that occurs mostly in elderly females. In this disease, B cells become malignant, accumulate in the dermis and subcutaneous tissue below the dermis to form red and violaceous skin nodules and tumors. These lesions typically occur on the lower extremities but in uncommon cases may develop on the skin at virtually any other site. In ~10% of cases, the disease presents with one or more skin lesions none of which are on the lower extremities; the disease in these cases is sometimes regarded as a variant of PCDLBL, LT termed primary cutaneous diffuse large B-cell lymphoma, other (PCDLBC-O). PCDLBCL, LT is a subtype of the diffuse large B-cell lymphomas (DLBCL) and has been thought of as a cutaneous counterpart to them. Like most variants and subtypes of the DLBCL, PCDLBCL, LT is an aggressive malignancy. It has a 5-year overall survival rate of 40–55%, although the PCDLBCL-O variant has a better prognosis than cases in which the legs are involved.

Günter Burg is a German dermatologist. Born in Mayen, Germany, he holds German and Swiss citizenship. He has been married to Dr. Doris Burg-Nicklas, a neurologist, since 1968. They have two sons: Andreas and Thomas.

References

  1. 1 2 3 4 5 6 7 8 Goodlad JR, Cerroni L, Swerdlow SH (January 2023). "Recent advances in cutaneous lymphoma-implications for current and future classifications". Virchows Archiv. 482 (1): 281–298. doi:10.1007/s00428-022-03421-5. PMC   9852132 . PMID   36278991.
  2. 1 2 3 Petrella T, Maubec E, Cornillet-Lefebvre P, Willemze R, Pluot M, Durlach A, Marinho E, Benhamou JL, Jansen P, Robson A, Grange F (December 2007). "Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?". The American Journal of Surgical Pathology. 31 (12): 1887–92. doi:10.1097/PAS.0b013e318068b527. PMID   18043044.
  3. 1 2 3 Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES (April 2019). "The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas". Blood. 133 (16): 1703–1714. doi:10.1182/blood-2018-11-881268. PMC   6473500 . PMID   30635287.
  4. ↑ Magro CM, Porcu P, Ahmad N, Klinger D, Crowson AN, Nuovo G (September 2004). "Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases". Applied Immunohistochemistry & Molecular Morphology. 12 (3): 216–24. doi:10.1097/00129039-200409000-00006. PMID   15551734.
  5. 1 2 3 4 5 Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD (September 2022). "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee". Blood. 140 (11): 1229–1253. doi:10.1182/blood.2022015851. PMC   9479027 . PMID   35653592.
  6. 1 2 Kempf W, Mitteldorf C, Cerroni L, Willemze R, Berti E, Guenova E, Scarisbrick JJ, Battistella M (August 2024). "Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group". Journal of the European Academy of Dermatology and Venereology. 38 (8): 1491–1503. doi:10.1111/jdv.19987. PMID   38581201.
  7. 1 2 3 Willemze R (June 2024). "Cutaneous lymphoproliferative disorders: Back to the future". Journal of Cutaneous Pathology. 51 (6): 468–476. doi: 10.1111/cup.14609 . PMID   38499969.
  8. ↑ Cheng J, Dávila Saldaña BJ, Chandrakasan S, Keller M (September 2024). "Pediatric lymphoproliferative disorders associated with inborn errors of immunity". Clinical Immunology. 266: 110332. doi:10.1016/j.clim.2024.110332. PMID   39069111.
  9. 1 2 3 4 5 6 7 8 9 Hathuc VM, Hristov AC, Smith LB (November 2017). "Primary Cutaneous Acral CD8+ T-Cell Lymphoma". Archives of Pathology & Laboratory Medicine. 141 (11): 1469–1475. doi: 10.5858/arpa.2017-0230-RA . PMID   29072952.
  10. 1 2 Bastidas Torres AN, Cats D, Out-Luiting JJ, Fanoni D, Mei H, Venegoni L, Willemze R, Vermeer MH, Berti E, Tensen CP (March 2022). "Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma". Haematologica. 107 (3): 702–714. doi:10.3324/haematol.2020.274506. PMC   8883537 . PMID   33792220.
  11. 1 2 Miano C, Megna M, Di Caterino P, Berti E, Fabbrocini G, Camela E (March 2021). "An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy: A new subtype?". Dermatologic Therapy. 34 (2): e14887. doi: 10.1111/dth.14887 . PMID   33595164.
  12. 1 2 3 Martinez-Escala ME, Kantor RW, Cices A, Zhou XA, Kaplan JB, Pro B, Choi J, Guitart J (September 2017). "CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder". Journal of the American Academy of Dermatology. 77 (3): 489–496. doi:10.1016/j.jaad.2017.05.015. PMID   28676328.
  13. 1 2 3 4 Prieto-Torres L, Camacho-García D, Piris MÁ, Requena L, Rodríguez-Pinilla SM (February 2021). "Atypical BCL6/GATA3+ Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma: A Diagnostic Challenge". The American Journal of Dermatopathology. 43 (2): 137–140. doi:10.1097/DAD.0000000000001737. PMID   32675470.
  14. 1 2 3 4 5 6 7 8 9 Kempf W, Petrella T, Willemze R, Jansen P, Berti E, Santucci M, Geissinger E, Cerroni L, Maubec E, Battistella M, Goodlad J, Guenova E, Lappalainen K, Ranki A, Craig P, Calonje E, Martin B, Whittaker S, Oschlies I, Wehkamp U, Nicolay JP, Wobser M, Scarisbruck J, Pimpinelli N, Stadler R, Kerl French K, Quaglino P, Lin J, Chen L, Beer M, Emanuel P, Dalle S, Robson A (May 2022). "Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop". The British Journal of Dermatology. 186 (5): 887–897. doi:10.1111/bjd.20973. PMID   34988968.
  15. 1 2 3 4 5 6 Stephan C, Grossman ME, Magro CM (2023). "Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder: A clinical and histologic retrospective cohort study". Clinics in Dermatology. 41 (6): 666–679. doi:10.1016/j.clindermatol.2023.09.002. PMID   37716580.
  16. ↑ Greenblatt D, Ally M, Child F, Scarisbrick J, Whittaker S, Morris S, Calonje E, Petrella T, Robson A (February 2013). "Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features". Journal of Cutaneous Pathology. 40 (2): 248–58. doi:10.1111/cup.12045. PMID   23189944.
  17. ↑ Kempf W, Kazakov DV, Cozzio A, Kamarashev J, Kerl K, Plaza T, Metze D (April 2013). "Primary cutaneous CD8(+) small- to medium-sized lymphoproliferative disorder in extrafacial sites: clinicopathologic features and concept on their classification" (PDF). The American Journal of Dermatopathology. 35 (2): 159–66. doi:10.1097/DAD.0b013e31825c3a33. PMID   22885550.
  18. 1 2 3 4 5 Tjahjono LA, Davis MD, Witzig TE, Comfere NI (September 2019). "Primary Cutaneous Acral CD8+ T-Cell Lymphoma-A Single Center Review of 3 Cases and Recent Literature Review". The American Journal of Dermatopathology. 41 (9): 644–648. doi:10.1097/DAD.0000000000001366. PMID   31433793.
  19. 1 2 3 Alberti-Violetti S, Fanoni D, Provasi M, Corti L, Venegoni L, Berti E (November 2017). "Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: A long-standing case with an unexpected progression". Journal of Cutaneous Pathology. 44 (11): 964–968. doi:10.1111/cup.13020. PMID   28796362.
  20. 1 2 3 4 Kempf W, Mitteldorf C (June 2021). "Cutaneous T-celGranule (cell biology)l lymphomas-An update 2021". Hematological Oncology. 39 Suppl 1: 46–51. doi:10.1002/hon.2850. PMID   34105822.
  21. ↑ Wobser M, Roth S, Reinartz T, Rosenwald A, Goebeler M, Geissinger E (June 2015). "CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas". The British Journal of Dermatology. 172 (6): 1573–1580. doi:10.1111/bjd.13628. PMID   25524664.
  22. ↑ Surmanowicz P, Doherty S, Sivanand A, Parvinnejad N, Deschenes J, Schneider M, Hardin J, Gniadecki R (2021). "The Clinical Spectrum of Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder: An Updated Systematic Literature Review and Case Series". Dermatology. 237 (4): 618–628. doi:10.1159/000511473. PMID   33326960.
  23. ↑ Kluk J, Kai A, Koch D, Taibjee SM, O'Connor S, Persic M, Morris S, Whittaker S, Cerroni L, Kempf W, Petrella T, Robson A (February 2016). "Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient". Journal of Cutaneous Pathology. 43 (2): 125–36. doi:10.1111/cup.12633. PMID   26423705.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.